The global clinical chemistry analyzers market size is expected to reach USD 25.88 billion by 2030, expanding at a CAGR of 4.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of chronic diseases is anticipated to be responsible for the high urgency to adopt clinical chemistry analyzers, which thereby widens the scope for growth during the forecast period. In addition, growing base of geriatric and bariatric population, which is highly susceptible to chronic diseases, is presumed to impel the demand further. Consequently, the resultant high sample volume requiring high capability analyzing devices is driving the market growth.
Moreover, increasing awareness pertaining to benefits associated with these devices is also a high impact rendering driver for clinical chemistry analyzers market. Advent of advanced chemistry analyzers has resulted in improved point-of-care testing capabilities, and thus created high potential growth opportunities for the market. In addition, technological advancements in preanalytical, analytical, and post analytical stages due to analyzing devices & reagents improved their diagnostic capabilities and overall efficiency, which is predicted to propel the growth further. These advancements include advent of microchips, sensors, chemometrics, and robotics. Furthermore, consistent efforts by public as well private healthcare organizations to increase the reliability of data have rapidly engendered the integration of automated chemistry analyzers and immunoassay systems, thereby resulting in overall reduction of workload in laboratories, thus propelling the demand.
Request a free sample copy or view report summary: Clinical Chemistry Analyzers Market Report
Based on product, the reagents segment led the market with the largest revenue share of 57.4% in 2023. The substantial share is predicted to be a consequence of a wide array of reagents present in the market, catering to different requirements of clinicians.
Based on the test type, the basic metabolic panel (BMP) segment held a market with the largest revenue share of 29.56% in 2023, owing to growing prevalence of lifestyle-induced diseases, such as obesity and other metabolic abnormalities.
Based on end-use, the hospitals segment led the market in 2023 with the largest revenue share of 58.32%, owing to the high patient volume, frequent readmissions, and large sample volumes.
North America dominated the market with the revenue share of 35.6% in 2023, due to rising healthcare spending in country, such as the U.S.
Asia Pacific region is anticipated to grow at the fastest CAGR during the forecast period owing to the presence of a large target population and increasing penetration of leading clinical chemistry product manufacturers in countries, such as India and China.
Grand View Research has segmented the global clinical chemistry analyzers market report based on product, test, end-use, and region:
Clinical Chemistry Analyzers Product Outlook (Revenue, USD Million, 2018 - 2030)
Analyzers
Small
Medium
Large
Very Large
Reagents
Calibrators
Controls
Standards
Others
Others
Clinical Chemistry Analyzers Test Outlook (Revenue, USD Million, 2018 - 2030)
Basic Metabolic Panel (BMP)
Electrolyte Panel
Liver Panel
Lipid Profile
Renal Profile
Thyroid Function Panel
Specialty Chemical Tests
Clinical Chemistry Analyzers End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Academic Research Centers
Diagnostic Laboratories
Others
Clinical Chemistry Analyzers Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
Spain
France
Italy
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Clinical Chemistry Analyzers Market
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Thermo Fisher Scientific, Inc.
Danaher Corporation (Beckman Coulter)
Abbott
Siemens Healthineers AG
F. Hoffmann-La Roche Ltd
Horiba, Ltd.
ELITech Group
QuidelOrtho Corporation
Randox Laboratories Ltd.
"The quality of research they have done for us has been excellent..."